Johnson & Johnson announced that it has entered into a definitive agreement to acquire Halda Therapeutics for $3.05B in cash. The transaction is expected to close within the next few months, subject to antitrust clearance and other customary closing conditions. The lead candidate, HLD-0915, is a clinical-stage therapy for prostate cancer. Under the terms of the agreement, Johnson & Johnson will acquire Halda. The transaction will be accounted for as a business combination and is expected to close within the next few months, subject to antitrust clearance and other customary closing conditions. The company expects dilution in 2026 of 15c to adjusted EPS due to short-term financing and a non-recurring charge related to the equity awards for Halda employees upon closing. Johnson & Johnson will provide commentary on full year 2026 guidance during the fourth quarter earnings call on Wednesday, January 21, 2026.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on JNJ:
- Johnson & Johnson to acquire Halda Therapeutics for $3.05B in cash
- Bristol Myers to stop Phase 3 Librexia ACS trial of milvexian
- Nike upgraded, Dollar Tree downgraded: Wall Street’s top analyst calls
- Scotiabank starts 10 large cap drugmakers with ‘out-of-consensus’ positive view
- Johnson & Johnson initiated with an Outperform at Scotiabank